Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TNF dose reduction in isolated limb perfusion.

D J Grünhagen1, J H W de Wilt, A N van Geel

  • 1Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, P.O. Box 5201, 3008 AE, Rotterdam, The Netherlands.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
|August 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of the gluteal turnover flap for perineal wound closure after abdominoperineal resection: randomized clinical trial.

BJS open·2026
Same author

ASO Visual Abstract: Clinical Course and Dedifferentiation in Atypical Lipomatous Tumors: A Retrospective Analysis of Surveillance and Surgical Management.

Annals of surgical oncology·2026
Same author

Near-infrared fluorescence imaging-guided surgery using cRGD-ZW800 to improve surgical resection margins in oral cancer: a phase I/II feasibility trial.

Nature communications·2026
Same author

A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trial.

BMC cancer·2026
Same author

Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT.

BMC cancer·2026
Same author

Clinical Course and Dedifferentiation of Atypical Lipomatous Tumors: A Retrospective Analysis of Surveillance and Surgical Management.

Annals of surgical oncology·2026

Reduced-dose TNF and melphalan isolated limb perfusion (TM-ILP) shows comparable efficacy and toxicity to standard doses for advanced limb sarcoma and melanoma. This finding supports dose reduction in TM-ILP for these rare conditions.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Pharmacology

Background:

  • Isolated limb perfusion with TNF and melphalan (TM-ILP) is a recognized treatment for advanced limb sarcomas and melanomas.
  • The optimal dosage of Tumor Necrosis Factor (TNF) in TM-ILP requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of TM-ILP using a reduced dose of TNF.
  • To compare outcomes of reduced-dose TM-ILP with standard-dose TM-ILP.

Main Methods:

  • A prospective analysis of 339 TM-ILPs from a single institution (1991-2003).
  • Focus on 64 procedures using reduced TNF doses (<3 mg for arms, <4 mg for legs).
  • Evaluation of response rates, toxicity, and patient outcomes.

Main Results:

Related Experiment Videos

  • Response rates and patient outcomes were comparable between reduced-dose and standard-dose TM-ILP for both melanoma and non-melanoma patients.
  • No statistically significant differences in local or systemic toxicity were observed.
  • Complete response rates for melanoma were 75% (reduced) vs. 69% (standard).

Conclusions:

  • TM-ILP with reduced TNF doses (≥1 mg) appears as effective as standard doses for advanced limb sarcomas and melanomas.
  • The rarity of these conditions makes large-scale non-inferiority trials challenging.